Result for
Tag: treatment
November 13, 2020
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
In a double-blind, randomized trial, adult outpatients with mild symptomatic COVID-19 treated with the SSRI antidepressant drug fluvoxamine had a lower likelihood of clinical deterioration over 15 days compared to placebo (8.7% absolute difference). The study included 152 participants and was conducted without patient contact. Clinical deterioration was defined as both (1) having shortness of…
November 9, 2020
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial
A multicenter, blinded, placebo-controlled randomized trial among 479 patients hospitalized with SARS-CoV-2 infection reported that treatment with hydroxychloroquine was not associated with changes in clinical status (on an ordinal scale from 1 as death to 7 as discharged with normal activities) 14 days following randomization (aOR 1.0, 95% CI 0.7-1.4), nor mortality 28 days following…
November 6, 2020
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
A randomized, open-label, phase 3 trial of remdesivir in hospitalized patients who did not require mechanical ventilation showed that there was no significant difference between a 5-day versus a 10-day course of treatment on the outcome of clinical status on a 7-point scale at day 14 in patients with confirmed SARS-CoV-2 infection. The authors note…
October 29, 2020
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
A phase 2 randomized placebo-controlled trial (n=452) interim analysis found that patients who received a 2800mg dose of monoclonal antibody LY-CoV555 could reduce SARS-CoV-2 log viral load by 3.4-fold after 11 days compared to patients receiving placebo, corresponding to a 0.53 log viral load reduction (95% CI: -0.98 to -0.08). Other patients receiving a 700mg…
Inhaled Corticosteroids and COVID-19 Risk and Mortality: A Nationwide Cohort Study
Use of inhaled corticosteroids (ICS) among patients with COPD or asthma was not associated with a COVID-19 diagnosis in a nationwide study conducted in Korea. In a nested case control study among patients with COPD with 640 COVID-19 cases and 2560 matched controls without COVID-19, ICS use was not associated with COVID-19 (aOR=1.02, 95% CI,…
October 26, 2020
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a blinded, randomized, controlled trial
[conference abstract, not peer-reviewed] Taking a two-week course of hydroxychloroquine did not prevent SARS-CoV-2 infection among household members of people with SARS-CoV-2 in a national, household-randomized trial in the US. Among participants who were SARS-CoV-2 negative at enrollment, there were 46 new infections among participants randomized to hydroxychloroquine (n=381) and 43 in the control participants…
October 23, 2020
Tocilizumab in Nonventilated Patients Hospitalized with Covid-19 Pneumonia
[Pre-print, not peer-reviewed] The randomized, placebo-controlled multi-country EMPACTA trial indicated that tocilizumab reduced the likelihood of progression to requiring mechanical ventilation or death in patients who were hospitalized with COVID-19 pneumonia and were not on a ventilator (n=389). The cumulative proportion of patients requiring mechanical ventilation or who had died by day 28 was 12%…
Early Use of Nitazoxanide in Mild Covid-19 Disease Randomized Placebo-Controlled Trial
[Pre-print, not peer-reviewed] A multicenter, randomized, placebo-controlled trial of the antiparasitic drug nitazoxanide indicated that for patients with mild COVID-19, at 1-week follow-up, 78% of patients (n=194) who had received nitazoxanide and 57% who had received placebo (n=198) reported complete resolution of symptoms (p=0.048). Swabs collected were negative for SARS-CoV-2 in 30% of patients in…
October 22, 2020
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
A randomized, placebo-controlled trial (n=243) demonstrated that tocilizumab (TCZ) was not effective in preventing intubation or death among moderately ill and hospitalized COVID-19 patients. At 28 days, the primary outcome of intubation or death was observed in 17 patients (10.6%) in the TCZ group and 10 patients (12.5%) in the placebo group (HR = 0.83,…
The Use of Intravenous Immunoglobulin Gamma for the Treatment of Severe Coronavirus Disease 2019: A Randomized Placebo-Controlled Double-Blind Clinical Trial
Results from a randomized placebo-controlled trial in Iran (n=59) suggest that administration of intravenous immunoglobin (IVIG) could reduce in-hospital mortality rates due to severe COVID-19. Mortality was 20% in the IVIG group (6 of 30) vs 48.3% (14 of 29) in the placebo group. Multivariate analysis showed that IVIG was associated with a reduced in-hospital…
Previous page Next page